混合治愈模型的样本大小计算,以限制的平均存活时间作为主要终点
Zhaojin Li1, Xiang Geng1, Yawen Hou2
1Department of Biostatistics, School of Public Health (Guangdong Provincial Key Laboratory of Tropical Disease Research), Southern Medical University, Guangzhou, Guangdong, China.
Statistical methods in medical research
|August 6, 2024
概括
这项研究引入了一种新的样本大小公式,用于使用受限平均存活时间的混合治愈模型,当违反比例危险假设时,它比日志等级测试更准确. 该方法通过计算患者治愈分数并提供可解释的生存时间差异来改进临床试验设计.
科学领域:
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
- 生存分析的分析.
背景情况:
- 许多临床试验,特别是在瘤学中,观察长期幸存者或"治愈"的患者,需要考虑治愈分数.
- 混合治愈模型的传统样本大小计算通常依赖于比例危险假设,这在实践中经常被违反.
- 使用日志等级测试的现有方法可能会导致不准确的样本大小估计,当比例危险不成立时.
研究的目的:
- 为混合治愈模型开发一个样本大小计算公式,使用受限平均存活时间 (RMST) 作为主要终点.
- 通过模拟和现实世界的例子来评估拟议的基于RMST的样本大小公式的准确性和效率.
- 为在临床试验中用治愈分数确定样本大小提供更强大的方法,特别是当不符合比例危险假设时.
主要方法:
- 基于受限平均存活时间 (RMST) 的混合治愈模型的新型样本大小公式.
- 进行模拟研究,以比较基于RMST的样本大小计算与传统的基于测试的日志排名方法的性能.
- 将开发的配方应用于子宫内膜癌试验的例子.
主要成果:
- 基于RMST的混合治愈模型的样本大小计算被发现是准确的,无论是否符合比例危险假设.
- 在违反比例危险假设的场景中,RMST方法通常需要较小的样本大小,与日志级别测试相比.
- RMST提供了临床上可解释的治疗效果指标 (例如,生存年数的差异),增强了患者与医生的沟通.
结论:
- 拟议的基于RMST的样本大小计算是混合治愈模型的更可靠的方法,特别是在违反比例危险的情况下.
- 这种方法提供了准确且往往更有效的样本大小估计,从而导致更好地设计的临床试验.
- RMST提供了一种实用且易于传播的治疗效益衡量方法,提高了试验结果的临床实用性.
相关概念视频
01:24Kaplan-Meier Approach
115
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
115
01:15Assumptions of Survival Analysis
114
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
114
01:20Comparing the Survival Analysis of Two or More Groups
166
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
166
01:20Actuarial Approach
69
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
69
01:09Censoring Survival Data
73
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
73
01:21Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334